Next generation pharmaceuticals
for NASH and diabetes
We are a drug discovery company focused on finding treatments for metabolic diseases. Through our cutting-edge research we have identified and patented the use of new molecules linked with insulin resistance and fatty liver diseases. One of our major discoveries is having shown that inhibiting the action of these molecules leads to the remission of NASH and diabetes.
Meet to the our team
Prof Carel Le Roux MD
Chief Medical Officer, Director of Medical Device Division, Investor
He is a leading Professor in metabolic science, has published numerous high-impact research papers in the field, and is an expert in obesity and diabetes.
Prof Francesco Rubino MD
Chief Officer for Obesity & Diabetes
He is a highly renowned bariatric surgeon and a leading researcher in obesity and diabetes.
Prof Geltrude Mingrone MD
Chief Advisor for Obesity & Diabetes
A passionate researcher, she has pushed forward the boundaries of metabolic medicine for the last 30 years and is among the most recognised researchers in metabolic medicine and diabetes research of our time.
Prof Phil Schauer MD
President, Chief Investment Officer
He is the CEO of Nutrition Capital Network, has substantial experience in fundraising and a wide expertise in advising nutrition companies.
Contact Us
Submit the following form Or contact us by email: info@ghpscientific.com